Everest Medicines Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Everest Medicines Limited
Calliditas Confident Of Keeping Ahead Of Travere In IgAN
The Swedish group’s Tarpeyo is reaping the benefits of an expanded US sales force and the company is confident of a big revenue rise in 2023, regardless of new competition in the IgAN field from Travere’s Filspari.
Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
Calliditas Spies Chinese Market As Tarpeyo Continues Upwards Sales Curve
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.
China mRNA COVID Vaccines Progress As Shanghai Rolls Out First Inhaled Shot
CanSino’s global-first inhaled COVID-19 vaccine is dosed into its first noses in Shanghai, while Zhejiang Haichang, Everest Medicines and Abogen make major progress with their respective mRNA vaccine programs.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.